Adverse outcome post acute coronary syndrome in diabetes

ISRCTN ISRCTN10805074
DOI https://doi.org/10.1186/ISRCTN10805074
Secondary identifying numbers Chinese National Science Foundation (Grant No 81300161)
Submission date
16/01/2017
Registration date
20/01/2017
Last edited
07/04/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Acute coronary syndrome (ACS) refers to a group of conditions due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. It encompasses a range of sudden heart conditions, including heart attack and unstable angina attack (sudden chest pain). ACS mainly happens due to narrowing of the blood vessels which supply the heart due to a build-up of plaque (a fatty, sticky substance) on the walls of arteries. Treatment for ACS can include surgery to unblock the blood vessels to supply he heart and use of blood thinning medications. Patients who have type 2 diabetes (a condition where the sufferer is unable to control their blood sugar levels properly) are known to have a higher rate of complications than previously healthy patients. Previous studies have shown that that a protein called pregnancy-associated plasma protein-A (PAPP-A) is a potentially important biomarker (natural indicator) of dangerous plaque and inflammation (swelling) in patients with ACS and has been identified in heart plaque. Patients with type 2 diabetes appeared to have high levels of PAPP-A than healthy people of the same age. The aim of this study is to find out whether increased levels of PAPP-A are an indicator of future heart and blood vessel complications after ACS.

Who can participate?
All patients who have been hospitalised for ACS who have had their PAPP-A levels measured.

What does the study involve?
After being admitted to hospital for ACS, participants are treated by cardiologists (heart doctors) as usual, following standard ACS treatment guidelines. Participants attend follow up appointments after 6, 12 and 24 months, where they are interviewed to find out if they have had any heart and blood vessel complications, such as stroke or heart attacks. This is then confirmed by reviewing medical records.

What are the possible benefits and risks of participating?
There are no direct benefits or risks involved to those participating.

Where is the study run from?
The Beijing Friendship Hospital Cardiovascular Center, Capital Medical University (China)

When is the study starting and how long is it expected to run for?
June 2012 to December 2014

Who is funding the study?
Chinese National Science Foundation (China)

Who is the main contact?
Professor Xue-Qiao Zhao
xueqiao@uw.edu

Contact information

Prof Xue-Qiao Zhao
Scientific

University of Washington
Harborview Medical Center
325 9th Avenue
Seattle
98104
United States of America

ORCiD logoORCID ID 0000-0001-7713-6369
Phone +1 (0)206 744 8305
Email xueqiao@uw.edu

Study information

Study designObservational study.
Primary study designObservational
Secondary study designLongitudinal study
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titlePregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes post-acute coronary syndrome in patients with type 2 diabetes mellitus
Study objectivesPregnancy-associated plasma protein-A (PAPP-A) is predictive for future adverse cardiovascular outcomes in patients with type-2 diabetes (T2DM).
Ethics approval(s)Beijing Friendship Hospital Institutional Review Board, 01/04/2012
Health condition(s) or problem(s) studied1. Acute coronary syndrome
2. Type-2 diabetes mellitus (T2DM)
InterventionAll study participants are enrolled into the study during their ACS hospitalization. During hosptialisation, participants are treated using standard techniques. This may include percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and medication, as decided by treating cardiologists following ACS treatment guidelines.

After hospital discharge, study participants are followed by their cardiologists for 24 months. After 6, 12 and 24 months, participants attend follow up visits at which the cardiovascular event rate is recorded.
Intervention typeOther
Primary outcome measure1. Cardiovascular death rate is assessed by medical record review and confirmed with death certificate at baseline, 6, 12 and 24 months of the 2 years of follow-up
2. Non-fatal MI rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up
3. Non-fatal stroke rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up
Secondary outcome measuresNo secondary outcome measures.
Overall study start date15/06/2012
Completion date30/12/2014

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants420
Key inclusion criteria1. Confirmed acute coronary syndrome
2. Has PAPP-A measurements
Key exclusion criteria1. Aystemic inflammatory disease or cancer
2. Missing PAPP-A measurements
Date of first enrolment15/06/2012
Date of final enrolment30/11/2012

Locations

Countries of recruitment

  • China

Study participating centre

The Beijing Friendship Hospital Cardiovascular Center, Capital Medical University
95th Yongan Road
Xicheng District
Beijing
10050
China

Sponsor information

Chinese National Science Foundation
Government

83 Shuangqing Road
Haidian District
Beijing
100085
China

Phone +86 (0)106 231 7474
Email webmaster@nsfc.gov.cn
ROR logo "ROR" https://ror.org/01h0zpd94

Funders

Funder type

Government

National Natural Science Foundation of China
Government organisation / National government
Alternative name(s)
Chinese National Science Foundation, Natural Science Foundation of China, National Science Foundation of China, NNSF of China, NSF of China, 国家自然科学基金委员会, National Nature Science Foundation of China, Guójiā Zìrán Kēxué Jījīn Wěiyuánhuì, NSFC, NNSF, NNSFC
Location
China

Results and Publications

Intention to publish date31/03/2017
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlans to public study results in the first quarter of 2017.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Moni Blazej Neradilek (moni@mwlight.com)

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 05/04/2017 Yes No

Editorial Notes

07/04/2017: Publication reference added.